LBX Pharmacy Chain Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

LBX Pharmacy Chain heeft een totaal eigen vermogen van CN¥7.5B en een totale schuld van CN¥4.0B, wat de schuld-eigenvermogensverhouding op 53.4% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥21.2B en CN¥13.7B. De EBIT LBX Pharmacy Chain is CN¥1.4B waardoor de rentedekking 14.7 is. Het heeft contanten en kortetermijnbeleggingen van CN¥2.1B.

Belangrijke informatie

53.4%

Verhouding schuld/eigen vermogen

CN¥4.03b

Schuld

Rente dekkingsratio	14.7x
Contant	CN¥2.10b
Aandelen	CN¥7.55b
Totaal verplichtingen	CN¥13.66b
Totaal activa	CN¥21.21b

Recente financiële gezondheidsupdates

Is LBX Pharmacy Chain (SHSE:603883) Using Too Much Debt?

Sep 02

LBX Pharmacy Chain (SHSE:603883) Seems To Use Debt Quite Sensibly

May 21

Recent updates

LBX Pharmacy Chain Joint Stock Company's (SHSE:603883) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Sep 06

Is LBX Pharmacy Chain (SHSE:603883) Using Too Much Debt?

Sep 02

Take Care Before Jumping Onto LBX Pharmacy Chain Joint Stock Company (SHSE:603883) Even Though It's 30% Cheaper

Jul 03

Here's Why We Think LBX Pharmacy Chain (SHSE:603883) Is Well Worth Watching

Jun 08

LBX Pharmacy Chain (SHSE:603883) Seems To Use Debt Quite Sensibly

May 21

There Is A Reason LBX Pharmacy Chain Joint Stock Company's (SHSE:603883) Price Is Undemanding

Apr 22

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥8.6B ) van 603883 } dekken niet de korte termijn passiva ( CN¥10.1B ).

Langlopende schulden: De kortetermijnactiva 603883 ( CN¥8.6B ) overtreffen de langetermijnschulden ( CN¥3.5B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 25.6% ) 603883 wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van 603883 is de afgelopen 5 jaar gestegen van 34.6% naar 53.4%.

Schuldendekking: De schuld van 603883 wordt goed gedekt door de operationele kasstroom ( 63.4% ).

Rentedekking: De rentebetalingen op de schuld van 603883 worden goed gedekt door EBIT ( 14.7 x dekking).

LBX Pharmacy Chain Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is LBX Pharmacy Chain (SHSE:603883) Using Too Much Debt?

LBX Pharmacy Chain (SHSE:603883) Seems To Use Debt Quite Sensibly

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of CN¥0.33 per share

LBX Pharmacy Chain Joint Stock Company to Report Q3, 2024 Results on Oct 30, 2024

Price target decreased by 12% to CN¥26.64

Investor sentiment deteriorates as stock falls 17%

Consensus EPS estimates fall by 29%

LBX Pharmacy Chain Joint Stock Company's (SHSE:603883) Price Is Right But Growth Is Lacking After Shares Rocket 30%

New minor risk - Share price stability

Investor sentiment improves as stock rises 23%

Now 23% undervalued after recent price drop

Is LBX Pharmacy Chain (SHSE:603883) Using Too Much Debt?

Take Care Before Jumping Onto LBX Pharmacy Chain Joint Stock Company (SHSE:603883) Even Though It's 30% Cheaper

Investor sentiment deteriorates as stock falls 17%

LBX Pharmacy Chain Joint Stock Company to Report First Half, 2024 Results on Aug 30, 2024

Dividend increased to CN¥0.66

Here's Why We Think LBX Pharmacy Chain (SHSE:603883) Is Well Worth Watching

LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 13, 2024

LBX Pharmacy Chain (SHSE:603883) Seems To Use Debt Quite Sensibly

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

There Is A Reason LBX Pharmacy Chain Joint Stock Company's (SHSE:603883) Price Is Undemanding

LBX Pharmacy Chain Joint Stock Company to Report Q1, 2024 Results on Apr 30, 2024

Investor sentiment improves as stock rises 18%

LBX Pharmacy Chain Joint Stock Company to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings released: EPS: CN¥1.36 (vs CN¥1.26 in FY 2021)

Now 21% undervalued after recent price drop

Price target increased by 8.1% to CN¥45.36

Now 21% undervalued after recent price drop

Price target increased by 7.5% to CN¥43.11

Price target increased to CN¥41.97

Now 22% undervalued

Now 21% undervalued

Less than half of directors are independent

Third quarter 2022 earnings: EPS misses analyst expectations

Investor sentiment deteriorated over the past week

Price target decreased to CN¥58.58

Consensus EPS estimates fall by 21%

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to CN¥63.49

Less than half of directors are independent

Third quarter 2021 earnings released: EPS CN¥0.31 (vs CN¥0.34 in 3Q 2020)

LBX Pharmacy Chain Joint Stock Company (SHSE:603883) agreed to acquire 51% stake in Hebei Hua Tuo Pharmacy Medicine Chain Co., Ltd. from Zhang Weijun, Tian Jinping, Ma Zhirong and Guo Zhihong fro CNY 1.4 billion.

Price target decreased to CN¥75.25

Second quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.35 in 2Q 2020)

Price target decreased to CN¥79.67

Price target decreased to CN¥86.50

First quarter 2021 earnings released: EPS CN¥0.56 (vs CN¥0.49 in 1Q 2020)

New 90-day low: CN¥61.85

New 90-day high: CN¥81.64

Investor sentiment improved over the past week

New 90-day low: CN¥63.60

New 90-day low: CN¥65.89

New 90-day low: CN¥67.21

Price target raised to CN¥97.98

Laobaixing Reportedly in Merger Talks with Yixintang

Third quarter earnings released

Laobaixing Pharmacy Chain Joint Stock Company to Report Q3, 2020 Results on Oct 30, 2020

Price target raised to CN¥89.75

New 90-day high - CN¥87.00

New 90-day high - CN¥87.00

First half earnings released

Laobaixing Pharmacy Chain Joint Stock Company to Report First Half, 2020 Results on Aug 21, 2020

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven